Efthymios Deliargyris
Hoofd Techniek/Wetenschap/O&O bij CYTOSORBENTS CORPORATION
Vermogen: 368 490 $ op 31-05-2024
Actieve functies van Efthymios Deliargyris
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CYTOSORBENTS CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-05-2020 | - |
Loopbaan van Efthymios Deliargyris
Eerdere bekende functies van Efthymios Deliargyris
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Hoofd Techniek/Wetenschap/O&O | 01-08-2018 | 30-04-2020 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01-01-2004 | 01-01-2010 |
| Wake Forest University | Corporate Officer/Principal | 01-01-2001 | 01-01-2004 |
Opleiding van Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Griekenland | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| CYTOSORBENTS CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
